Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Recipharm Unit Files for Infectious Disease Treatment | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances, Trials & Filings

Recipharm Unit Files for Infectious Disease Treatment

Will co-market first-in-class generic with Astimex

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

RPH Pharmaceuticals, a subsidiary of Recipharm AB, has filed an application for an undisclosed infectious disease drug product in a range of European countries. The product has been developed through a partnership with Swedish pharmaceutical company, Astimex Pharma AB, which will to market the product in the Nordic market.
 
The product, owned by RPH Pharmaceuticals, is a “first-in-class generic” and will be licensed to third parties for distribution in markets where Astimex presently is not represented.
 
Astimex and RPH have expanded their collaboration with another manufacturing and development project in which the drug target is another first-in-class generic approved for use in most of the North European markets. Under the collaboration, Recipharm builds a registration dossier while Astimex takes full responsibility for sales and distribution in the Swedish market; RPH Pharmaceuticals can out-license sales and distribution rights in other markets.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics